The Filing Desk

PMGC Holdings

ELAB · Nasdaq · Health Care · Financials, fiscal 2022 to 2025

ELAB · Last close · November 19, 2026
$1.27
Value PMGC Holdings yourself

PMGC Holdings reported revenue of $1 million in fiscal 2025. Its net margin was −1,313.0%. Free cash flow was −$6 million. The diluted share count rose 2049.1%.

PMGC HOLDINGS INC. Latest fiscal year ended December 31, 2025 10-K filed March 30, 2026 · 0001213900-26-035937 Updated
Revenue
$1M
 
Net margin
−1,313.0%
 
Net income
−$8M
 
Free cash flow
−$6M
 
Return on equity
−106.9%
12.2 pts
Market cap
$1M
Nov 19 close
P/E
—
 

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. The SEC's structured data gives diluted share counts for fiscal 2022 in thousands without saying so; they are shown here in millions, which makes net income per share match the reported earnings per share.

Charts show fiscal years, from the 10-K filings.

What PMGC Holdings does

PMGC Holdings is a small holding company that owns four businesses in unrelated fields and says it wants to buy more. Two of them, bought in July 2025, bring in its sales: Pacific Sun Packaging, based in San Clemente, California, designs and supplies protective trays and carriers for computer parts such as processors, memory modules and drives, for over 300 business customers in North America; and AGA Precision Systems, a California machine shop that cuts precision metal parts, including from titanium, for aerospace, defense and industrial customers.

The third, Northstrive Biosciences, is developing drugs. Its main candidate, EL-22, is a modified probiotic meant to help people keep muscle while taking weight-loss drugs such as GLP-1 medicines. It has finished an early safety trial in healthy volunteers in South Korea, and the company plans to seek approval from the US Food and Drug Administration to begin testing in patients, alone or with a partner, if it has the money. It names Novo Nordisk, Eli Lilly and Pfizer among the companies working on obesity treatments. The fourth, PMGC Capital, invests in and lends to other businesses.

The company used to sell skin-care products and sold that business in January 2025. It has 32 full-time employees. It lost $7,747,813 in 2025 and warns that there is doubt about its ability to keep operating without raising more money.

Its biggest risks, as it describes them

  • Doubt about whether it can keep operating, given its continuing losses and limited cash.
  • Spending far more cash than it earns, leaving it dependent on raising money from investors or lenders.
  • Trouble integrating the businesses it buys, or those businesses losing key owners, staff or customers.
  • Its drug candidates may fail in testing or never win approval, or it may lack the money to develop them.
From PMGC Holdings's annual report on Form 10-K, filed March 30, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

PMGC Holdings lost money in fiscal 2025: a net loss of $8 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25
Cash and short-term investments1346
Debt incl. finance leases———0
Net debt (negative means net cash)———−6
Net debt to EBITDA————
Debt to equity———0.0x
Interest coverage——−4.5x−29.1x
Current ratio2.6x3.8x3.4x1.7x
Quick ratio2.2x3.4x—1.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project PMGC Holdings' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of PMGC Holdings reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−143.2%——
Altman Z''—−1.16−6.11
Accruals ratio7.2%−10.7%−16.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rose—PassPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assets———
Current ratio rosePassFailFail
Share count didn't risePassPassFail
Gross margin rosePass——
Revenue rose relative to assets———
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put PMGC Holdings side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
PMGC HoldingsFY25——−1,080.5%———
Cardiff OncologyFY25−13.2%−8,256.3%−6,402.5%——2Compare
Silence TherapeuticsFY25−98.7%−16,292.8%−11,149.5%———Compare
ImageneBioFY25−77.1%−6,056.4%————Compare
BioRestorative TherapiesFY25−10.3%−4,350.1%−3,031.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

4 years of figures

Fiscal yearFY22FY23FY24FY25
Income statement
Revenue12—1
Revenue growth—123.5%——
Gross profit01—0
Research and development0000
Operating income————
Net income−2−4−6−8
Diluted EPS (US$)−0.19−0.40−4,239.70−382.30
Diluted shares (millions)10000
Cash flow
Cash from operations−2−5−6−6
Capital expenditure0000
Free cash flow−2−5−6−6
Dividends paid0000
Share buybacks0000
Acquisitions0002
Stock-based compensation000−0
Balance sheet at fiscal year end
Cash and short-term investments1346
Debt incl. finance leases———0
Total assets25913
Total liabilities1125
Shareholders' equity1478
Margins and ratios
Gross margin58.4%66.2%—31.4%
Operating margin————
Net margin−234.9%−251.2%—−1,313.0%
Free cash flow margin−211.6%−266.7%—−1,080.5%
Rule of 40 (growth + FCF margin)—−143.2%——
Return on capital————
Return on equity—−173.5%−119.1%−106.9%
Return on assets—−121.5%−88.1%−70.9%
Net debt to EBITDA————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: PMGC Holdings' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with PMGC Holdings.